Dirk R. Wijnen schreef:
DSM and Crucell Announce PER.C6® Technology Milestone
Leiden, The Netherlands/Parsippany, USA, 11 March 2008 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that another important milestone has been achieved with the PER.C6® technology platform for the production of monoclonal antibodies and recombinant proteins. Scientists working at PERCIVIA reached a record level titer of 15 g/L at harvest for an antibody product. PERCIVIA is the PER.C6® Development Center joint venture between DSM and Crucell, located in Cambridge, Massachusetts, USA.
Marco Cacciuttolo, CEO of PERCIVIA comments, "This high titer achievement for PER.C6®, the highest reported to date, marks a major event for the biopharmaceutical industry. It demonstrates the power and robustness of the PER.C6® manufacturing platform and it clearly shows that the PER.C6® manufacturing platform will have a major impact to the overall economics of manufacturing biopharmaceuticals. DSM and Crucell recognized the enormous potential of the PER.C6® technology when starting the PERCIVIA joint venture just over 1 year ago. The breakthrough results achieved in a single year reinforce the special properties and abilities of the PER.C6® manufacturing platform. Based on our scientific data today, we are confident that we will be able to drive productivity even further."
Marcel Lubben, VP of Marketing, Sales & Business Development at DSM Biologics added, "We are very enthusiastic about the new 15 g/L milestone for our licensees. The PER.C6® manufacturing platform has tremendous potential for the biotech industry to significantly reduce the cost-of-goods for monoclonal antibodies and recombinant proteins, resulting in more affordable therapeutic treatments for patients."
Martina Molsbergen, VP Business Development at Crucell, added "The PER.C6® platform can reduce the risk of supply limitations and potentially postpone major capital expenditure decision hurdles for drug development companies. The 15 g/L milestone is instrumental in the further market penetration of the PER.C6® technology."